Method of increasing muscle mass by administering a myostatin binding agent
View Patent ↗The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
1. A method of increasing lean muscle mass in a subject comprising administering a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a therapeutically effective amount of a myostatin binding agent wherein the myostatin binding agent has the structure:
(X 1 ) a —F 1 —(X 2 ) b , or multimers thereof;
wherein F 1 is a vehicle; and X 1 and X 2 are each independently selected from
-(L 1 ) c -P 1 ;
-(L 1 ) c -P 1 -(L 2 ) d -P 2 ;
-(L 1 ) c -P 1 -(L 2 ) d -P 2 -(L 3 ) e -P 3 ;
and -(L 1 ) c -P 1 -(L 2 ) d -P 2 -(L 3 ) e -P 3 -(L 4 ) f -P 4 ;
wherein P 1 , P 2 , P 3 , and P 4 are peptides capable of binding myostatin, wherein L 1 , L 2 , L 3 , and L 4 are each linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1, and
wherein one or more of the peptides capable of binding myostatin comprise the amino acid sequence Cb 1 b 2 Wb 3 WMCPP (SEQ ID NO: 353), wherein
b 1 is selected from any one of the amino acids T, I, or R;
b 2 is selected from any one of R, S, Q;
b 3 is selected from any one of P, R and Q,
and wherein the peptide is between 10 and 50 amino acids in length, and physiologically acceptable salts thereof.
2. A method of increasing the ratio of lean muscle mass to fat in a subject comprising administering a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a therapeutically effective amount of a myostatin binding agent wherein the myostatin binding agent has the structure:
(X 1 ) a —F 1 —(X 2 ) b , or multimers thereof;
wherein F 1 is a vehicle; and X 1 and X 2 are each independently selected from
-(L 1 ) c -P 1 ;
-(L 1 ) c -P 1 -(L 2 ) d -P 2 ;
-(L 1 ) c -P 1 -(L 2 ) d -P 2 -(L 3 ) e -P 3 ;
and -(L 1 ) c -P 1 -(L 2 ) d -P 2 -(L 3 ) e -P 3 -(L 4 ) f -P 4 ;
wherein P 1 , P 2 , P 3 , and P 4 are peptides capable of binding myostatin, wherein L 1 , L 2 , L 3 , and L 4 are each linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1, and
wherein, the one or more of the peptides capable of binding myostatin comprise the amino acid sequence Cb 1 b 2 Wb 3 WMCPP (SEQ ID NO: 353), wherein
b 1 is selected from any one of the amino acids T, I, or R;
b 2 is selected from any one of R, S, Q;
b 3 is selected from any one of P, R and Q,
and wherein the peptide is between 10 and 50 amino acids in length, and physiologically acceptable salts thereof.
3. A method of treating a muscle-wasting disease in a subject comprising administering a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a therapeutically effective amount of a myostatin binding agent wherein the myostatin binding agent has the structure:
(X 1 ) a —F 1 —(X 2 ) b , or multimers thereof;
wherein F 1 is a vehicle; and X 1 and X 2 are each independently selected from
-(L 1 ) c -P 1 ;
-(L 1 ) c -P 1 -(L 2 ) d --P 2 ;
-(L 1 ) c -P 1 -(L 2 ) d -P 2 -(L 3 ) e -P 3 ;
and -(L 1 ) c -P 1 -(L 2 ) d -P 2 -(L 3 ) e -P 3 -(L 4 ) f -P 4 ;
wherein P 1 , P 2 , P 3 , and P 4 are peptides capable of binding myostatin, wherein L 1 , L 2 , L 3 , and L 4 are each linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1, and
wherein, the one or more of the peptides capable of binding myostatin comprise the amino acid sequence Cb 1 b 2 Wb 3 WMCPP (SEQ ID NO: 353), wherein
b 1 is selected from any one of the amino acids T, I, or R;
b 2 is selected from any one of R, S, Q;
b 3 is selected from any one of P, R and Q,
and wherein the peptide is between 10 and 50 amino acids in length, and physiologically acceptable salts thereof.
4. The method of claim 3 , wherein the disease is selected from muscular dystrophy, amyotrophic lateral sclerosis, congestive obstructive pulmonary disease, chronic heart failure, cancer, AIDs, renal failure, uremia, rheumatoid arthritis, age-related sarcopenia, and muscle-wasting due to prolonged bedrest, spinal chord injury, stroke, bone fracture, and aging.